ArticleKidney3602026
Association between Urinary Fractional Excretion of Potassium and Proteinuria Remission in Adult Nephrotic Syndrome.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
key pointsElevated fractional excretion of potassium (FEK) at biopsy predicts a lower rate of proteinuria remission in adults with nephrotic syndrome. FEK levels vary by histologic types, being low in minimal change disease and high in diabetic kidney disease, suggesting diagnostic utility. FEK shows a dose-dependent link with remission, supporting its use as a simple prognostic biomarker.
backgroundReliable prognostic biomarkers of nephrotic syndrome (NS) are crucial for optimizing patient management. The fractional excretion of potassium (FEK) reflects net tubular potassium handling, but its association with prognosis in NS remains unexplored. We aimed to investigate the association between baseline FEK and proteinuria remission in adult NS.
methodsThis multicenter retrospective cohort study was conducted across nine institutions in Japan. We enrolled adult patients diagnosed with NS who underwent a native kidney biopsy and had FEK between January 2012 and June 2022. Patients were categorized based on FEK levels and followed until the first complete remission of proteinuria.
resultsA total of 401 patients (median age, 61 years; 43% female) were included. Study participants were stratified into two groups based on the FEK cutoff value of 10%. Patients with high FEK had a significantly lower cumulative incidence of complete remission compared with those with low FEK ( P < 0.001, log-rank test). In multivariable Cox regression analysis, high FEK was independently associated with a lower likelihood of complete remission (hazard ratio, 0.53; 95% confidence interval, 0.36 to 0.78). The trend of this association was observed across most subgroups, including those based on histologic diagnosis of minimal change disease and non-minimal change disease. Further stratification into four FEK categories revealed a progressive decline in remission rates with increasing FEK, indicating a dose-dependent relationship.
conclusionsElevated FEK is an independent predictor of a lower likelihood of proteinuria remission in Japanese adults with NS. FEK may serve as a readily accessible and valuable prognostic biomarker in the clinical management of NS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.